This week’s Litigators of the Week, Daralyn Durie, Eugene Novikov and Kira Davis of Durie Tangri scored a nine-digit infringement verdict for Plexxikon, the Berkeley, California-based developer of the first FDA-approved targeted therapy for metastatic melanoma — the deadliest form of skin cancer in the U.S.

After an eight-day trial in front of U.S. District Judge Haywood Gilliam Jr., a federal jury in Oakland last week found that Novartis Pharmaceuticals Corp. not only infringed Plexxikon’s patents, but did so willfully. The verdict included the entire $177.8M damages amount Plexxikon was seeking.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]